AttendMe Owl Logo
AttendMe
Sign In
All Pathways
Infectious DiseaseManagement

Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025)

Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025): Active Tuberculosis → Initial Workup → Respiratory Isolation → Drug Susceptibility → Drug-Susceptible TB.

Pathway Overview

12 steps

Algorithm Steps

12 total

  1. 01Start

    Active Tuberculosis

    Pulmonary or extrapulmonary TB confirmed or highly suspected

  2. 02Action

    Initial Workup

    Before starting treatment

    • Sputum x3 for AFB smear and culture
    • GeneXpert MTB/RIF for rapid detection
    • CXR
    • HIV test (mandatory)
    • Baseline LFTs, CBC, BMP, visual acuity
  3. 03Action

    Respiratory Isolation

    Airborne precautions

    • Negative pressure room
    • N95 respirators for staff
    • Until 3 negative smears on treatment
  4. 04Decision

    Drug Susceptibility

    Based on GeneXpert and/or culture

  5. 05Action

    Drug-Susceptible TB

    Standard 4-drug regimen

    • Intensive phase (2 months): RIPE
    • R: Rifampin 10mg/kg (max 600mg) daily
    • I: Isoniazid 5mg/kg (max 300mg) daily + B6
    • P: Pyrazinamide 25mg/kg daily
    • E: Ethambutol 15-20mg/kg daily
  6. 06Action

    Continuation Phase

    After 2 months intensive

    • 4 months Rifampin + Isoniazid (total 6 months)
    • NEW: 4-month regimen option:
    • HPZM (INH, RIF, PZA, Moxifloxacin) if age ≥12, drug-susceptible
    • Continue pyridoxine (B6) throughout
  7. 07Action

    Monitoring

    Clinical and laboratory

    • Monthly sputum until culture negative
    • LFTs at baseline, then if symptomatic
    • Visual acuity monthly while on ethambutol
    • DOT strongly recommended
  8. 08Warning

    Hepatotoxicity

    ALT >5x ULN or symptoms

    • Stop all hepatotoxic drugs
    • Rechallenge sequentially after normalization
    • Consider alternative regimen
  9. 09Action

    HIV Co-infection

    Special considerations

    • Start ART within 2-8 weeks of TB treatment
    • Watch for IRIS
    • Drug interactions: Rifabutin may substitute for rifampin
    • Longer duration may be needed
  10. 10Outcome

    Treatment Complete

    6+ months, cultures negative

  11. Path rejoins step 10Shared downstream outcome
  12. 11Warning

    Treatment Failure/Relapse

    Persistent positive cultures, recurrence

    • Re-test for drug resistance
    • Ensure DOT compliance
    • Consider surgical resection if localized
  13. 12Action

    MDR-TB (RIF-resistant)

    Specialist consultation required

    • 6-month BPaLM regimen now recommended:
    • Bedaquiline + Pretomanid + Linezolid + Moxifloxacin
    • OR longer regimen based on DST
    • Expert consultation essential
  14. Path rejoins step 07Shared downstream outcome

Guideline Source

ATS/CDC/ERS/IDSA Treatment Guidelines 2025

DOI: 10.1164/rccm.202410-2096STView Guideline

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • ⚠️ UNVALIDATED DRAFT: This algorithm was AI-generated from guideline summaries and has NOT been reviewed by clinical experts. All doses, thresholds, and pathways MUST be verified against primary sources by qualified clinicians before clinical use. Do not use for patient care without expert validation.
  • Drug resistance patterns critical
  • HIV coinfection requires special consideration
  • Hepatotoxicity monitoring essential
  • DOT recommended

Applicable Regions

USEU
Version 1Next review: 2027-01-11

Related Infectious Disease Pathways

Bacterial Meningitis Management (IDSA 2004)

Emergency

Candidemia & Invasive Candidiasis Management (IDSA 2016)

Management

Cellulitis & Skin/Soft Tissue Infection Management (IDSA 2014)

Management

Central Line-Associated Bloodstream Infection Management

Management

Next steps

Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.

Calculator

CURB-65 Score

Pneumonia severity and disposition

Open page

Compare

AttendMe.ai vs OpenEvidence

See how this pathway workflow compares against OpenEvidence.

Open page

Commercial

Start free

Run the pathway in a live AttendMe account with citations and tracked usage.

Start free

Related Resources

All Clinical PathwaysClinical CalculatorsAI Chat with Auto-Detection

Frequently Asked Questions

What is the Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025)?

The Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025) is a management clinical algorithm for Infectious Disease. It provides a structured decision tree to guide clinical decision-making, based on ATS/CDC/ERS/IDSA Treatment Guidelines 2025.

What guideline is the Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025) based on?

This algorithm is based on ATS/CDC/ERS/IDSA Treatment Guidelines 2025 (DOI: 10.1164/rccm.202410-2096ST).

What are the limitations of the Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025)?

Known limitations include: ⚠️ UNVALIDATED DRAFT: This algorithm was AI-generated from guideline summaries and has NOT been reviewed by clinical experts. All doses, thresholds, and pathways MUST be verified against primary sources by qualified clinicians before clinical use. Do not use for patient care without expert validation.; Drug resistance patterns critical; HIV coinfection requires special consideration; Hepatotoxicity monitoring essential; DOT recommended. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free